Vantage Biosciences

Vantage Biosciences is a UK-based clinical stage biotechnology company focused on preventing vision loss caused by diabetes. They target the initial neuroinflammatory processes that damage the eye's neurovascular unit before microangiopathy becomes severe. Their goal is to develop disease-modifying drugs that intervene at the earliest biological stages of diabetic eye disease, aiming to provide patients with therapies that address the root cause of the condition.